330 Firstline maintenance parp inhibitors in advanced ovarian cancer: a network meta-analysis for comparative efficacy and adverse events. (13th November 2020)

• Record Type: Journal Article
• Authors: Haddad, P; Gallagher, K; Hammoud, D
• Is Part Of: International journal of gynecological cancer. Volume 30(2020)Supplement 3
• Page Start: A133
• Page End: A134
• Publication Date: 2020-11-13
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2020-IGCS.283
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Background: Several studies explored the clinical benefit of maintenance PARP inhibitors (PARPI) and antiangiogenic agents (AA) in advanced ovarian cancer (aOC) with varied results. We conducted this analysis to expand our knowledge of the relative adverse-events (AE) and efficacy of firstline maintenance PARPI and AA in aOC. Methods: A review of the medical literature was conducted using online databases. Inclusion criteria consisted of English language; diagnosis of aOC; firstline maintenance treatment with Olaparib (O), Niraparib (NR), Veliparib (V), Bevacizumab (B), Pazopanib (P), Nintedanib (NN), and control (C); and phase 3 randomized studies reporting progression, death, and AE. A frequentists and Bayesian network meta-analyses were conducted using netmeta package and random-effects model. Results: Seven studies comprising 7, 770 participants were included. The relative risk (RR) of progression and death (P&D) was highest in C and B>NN>P/V/NR/O in decreasing order. RR of AE≥3 was highest in P>NR>O/NN/B/V/C in decreasing order. PARPI significantly improved PFS in patients with homologous-recombinant deficiency (HRD) + or -, BRCA + or -, BRCA2+, and Stages 3 and 4. PARPI demonstrated an equivalent reduction in RRP&D in BRCA+ patients. In HRD+, O had the lowest RRP&D followed by NR then V in increasing order. However, in HRD-, V had the lowest RRP&D followed by NR then O. Conclusions: This network meta-analysis is the first to compare and rank firstline maintenance therapies in aOC. It indicates that PARPI have better outcomes than AA. It also demonstrates that individual PARPI vary in frequency of AE≥3 as well as clinical efficacy across mutation subtypes.